Santen Pharmaceutical Co Ltd (4536.T) Key Developments | Reuters.com
Edition:
United States

Santen Pharmaceutical Co Ltd (4536.T)

4536.T on Tokyo Stock Exchange

1,593JPY
28 Jun 2016
Change (% chg)

¥63 (+4.12%)
Prev Close
¥1,530
Open
¥1,511
Day's High
¥1,600
Day's Low
¥1,507
Volume
2,500,100
Avg. Vol
1,652,845
52-wk High
¥2,163
52-wk Low
¥1,423

Latest Key Developments (Source: Significant Developments)

SANTEN PHARMACEUTICAL raises year-end dividend forecast for FY 2016
Tuesday, 23 Feb 2016 02:00am EST 

SANTEN PHARMACEUTICAL CO LTD:Raised year-end dividend forecast to 13 yen per share from 12 yen per share for FY ending March 2016.  Full Article

SANTEN PHARMACEUTICAL assigns anti-rheumatic pharmaceuticals business to Hyperion Pharma
Monday, 3 Aug 2015 03:00am EDT 

SANTEN PHARMACEUTICAL CO LTD:Assigned its anti-rheumatic pharmaceuticals business to Hyperion Pharma, under a simplified company-split method, effective Aug. 3.  Full Article

SANTEN PHARMACEUTICAL announces assignment of anti-rheumatic pharmaceuticals business to Hyperion Pharma
Tuesday, 12 May 2015 02:20am EDT 

SANTEN PHARMACEUTICAL CO LTD:To enter an agreement with Showa Yakuhin Kakou Co., Ltd. and Hyperion Pharma Co., Ltd. to assign its anti-rheumatic pharmaceuticals business to Hyperion Pharma, under a simplified company-split method, effective Aug. 3.To receive 45 bln yen in cash from Hyperion Pharma.After completion of the assignment, Showa Yakuhin intends to merge its pharmaceutical business with the anti-rheumatic pharmaceuticals business succeeded by Hyperion Pharma.  Full Article

R-Tech Ueno to acquire development and business right of ophthalmic from SANTEN PHARMACEUTICAL
Monday, 27 Apr 2015 02:30am EDT 

R-Tech Ueno Ltd:To acquire development and business right of ophthalmic named DE-105 from SANTEN PHARMACEUTICAL CO LTD.DE-105 is used for treatment of persistent corneal epithelial defect.  Full Article

SANTEN PHARMACEUTICAL announces approval of Ikervis for EU marketing authorization
Wednesday, 25 Mar 2015 04:00am EDT 

SANTEN PHARMACEUTICAL CO LTD:Received approval of the Marketing Authorization Application (MAA) for Ikervis from the European Commission (EC).Ikervis is approved for treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes.  Full Article

SANTEN PHARMACEUTICAL raises year-end dividend forecast for FY 2015
Tuesday, 24 Mar 2015 03:00am EDT 

SANTEN PHARMACEUTICAL CO LTD:Says it raised the year-end dividend forecast to 60 yen per share from 50 yen per share for the FY ending March 2015.  Full Article

SANTEN PHARMACEUTICAL raises consolidated full-year outlook for FY 2015
Tuesday, 24 Mar 2015 03:00am EDT 

SANTEN PHARMACEUTICAL CO LTD:Says the company raised the consolidated full-year outlook for the FY ending March 2015 (based on Japan-Generally Accepted Accounting Principles).Revenue forecast increased to 161,000 million yen from 156,000 million yen.Operating profit forecast increased to 33,000 million yen from 30,000 million yen.Ordinary profit forecast increased to 33,500 million yen from 30,000 million yen.Net profit forecast increased to 22,000 million yen from 19,500 million yen.Earnings per share forecast increased to 266.34 yen from 236.26 yen.Comments that revenue of ophthalmic product higher than expected is the main reason for the forecast.  Full Article

European Medicines Agency accepts SANTEN PHARMACEUTICAL CO LTD's Marketing Application Filing for Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis of the Posterior Segment
Monday, 2 Mar 2015 03:24am EST 

SANTEN PHARMACEUTICAL CO LTD:Says the European Medicines Agency (EMA) has accepted the company's Marketing Authorization Application (MAA) filing for the use of intravitreal sirolimus, an investigational mTOR inhibitor, for the treatment of noninfectious uveitis (NIU) of the posterior segment.Says the MAA filing marks the beginning of a regulatory review process for intravitreal sirolimus, which has the potential to address an unmet need in the European Union (EU) where NIU of the posterior segment is a leading cause of blindness.Says the EMA submission is supported by data from SAKURA ( S tudy A ssessing double-mas K ed U veitis t R e A tment), a pivotal Phase 3 study.Says the submission seeks approval to market the sirolimus, 440 ug dose for the chronic treatment of NIU of the posterior segment of the eye.  Full Article

DURECT Corp enters into license agreement granting SANTEN the worldwide rights to Sustained Release SABER Ophthalmology Product
Tuesday, 16 Dec 2014 08:00am EST 

DURECT Corp:Enters into an agreement with Santen Pharmaceutical Co., Ltd. granting Santen the exclusive worldwide rights to develop and commercialize a sustained release product utilizing DURECT's SABER technology to deliver an ophthalmology drug.Under the terms of the agreement, Santen will pay DURECT an upfront fee of $2 mln in cash and make contingent cash payments to the company upon the achievement of certain development and commercialization milestones.  Full Article

SANTEN PHARMACEUTICAL CO LTD completes to acquire ophthalmology assets from Merck & Co., Inc. (second time)
Thursday, 2 Oct 2014 03:00am EDT 

SANTEN PHARMACEUTICAL CO LTD:Completed to acquire ophthalmology assets from Merck & Co., Inc. (second time) with amount of 5.3 billion yen on Oct. 1.Plan disclosed on May 13 and the acquisition of first time was on July 2.  Full Article